



Rexahn Pharmaceuticals, Inc.
Investor Relations Department
15245 Shady Grove Road, Suite
455
Rockville, MD 20850
United States

Visit IR website [↗](#)
Sign-up for email alerts [↗](#)

AMEX: RNN

Last Trade:	2.36
Trade Time:	3:59 PM ET 07/26/17
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	1.27 - 7.10
Volume	N/A

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to developing best-in-class therapeutics for the treatment of cancer. Rexahn currently has three clinical stage oncology candidates, Archexin®, RX-3117, and Supinixin™ (RX-5902) and a robust pipeline of preclinical compounds to treat multiple types of cancer.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- 07/10/17**
[Rexahn Pharmaceuticals Receives Notice of Allowance for a New U.S. Patent Covering the Use of RX-3117](#)
- 06/07/17**
[Rexahn Announces \\$10 Million Registered Direct Offering](#)
- 06/04/17**
[Rexahn Pharmaceuticals Presents Preliminary Efficacy Data from the Ongoing Phase IIa Clinical Trial of RX-3117 in Metastatic Bladder Cancer at the American Society of Clinical Oncology \(ASCO\) 2017 Annual Meeting](#)
- 05/08/17**
[Rexahn Pharmaceuticals to Present RX-3117 Clinical Data at the American Society of Clinical Oncology \(ASCO\) 2017 Annual Meeting](#)
- 05/05/17**
[Rexahn Effects 1-for-10 Reverse Stock Split](#)

Financials [\[View all \]](#)

- [Fourth Quarter Financial Results](#)
- 02/24/17**
[Annual Report \(10-K\)](#)
- 02/24/17**
[Proxy Statement \(DEF 14A\)](#)
- 05/03/17**
[Quarterly Report \(10-Q\)](#)
- 11/04/16**
[Quarterly Report \(10-Q\)](#)
- 08/05/16**
[Quarterly Report \(10-Q\)](#)